Regulation - Pricing

Filter

Current filters:

Pricing

Popular Filters

176 to 200 of 324 results

More transparency on medicine pricing called for by EU parliamentarians

19-12-2012

More transparency and precise time limits for decision-making on pricing and reimbursement of medicines…

EuropeGenericsPharmaceuticalPricingRegulation

Eisai disagrees with Germany's IQWiG report on epilepsy drug Fycompa

19-12-2012

In the assessment report by the German Institute for Quality and Efficiency in Health Care (IQWiG) on…

EisaiEuropeFycompaNeurologicalPharmaceuticalPricingRegulation

Australian review finds more work needed on new anticoagulants

19-12-2012

A report into anticoagulation therapies released yesterday by Australian Minister for Health Tanya Plibersek…

Asia-PacificBoehringer IngelheimCardio-vascularPharmaceuticalPradaxaPricingRegulation

UK's NICE says Roche's Avastin not cost effective for advanced ovarian cancer

18-12-2012

The UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) has published…

AvastinBiotechnologyEuropeOncologyPharmaceuticalPricingRegulationRoche

Once again, no proof of added benefit found for Boehringer/Lilly's Trajenta by Germany's IQWiG

13-12-2012

Once again, the German Institute for Quality and Efficiency in Health Care (IQWiG) has found no added…

Boehringer IngelheimDiabetesEli LillyEuropePharmaceuticalPricingRegulationTrajenta

Scottish Medicines Consortium approves Eisai's Fycompa and Novartis' Lucentis for DME

11-12-2012

Japanese drug major Eisai's (TYO: 4523) Fycompa (perampanel), a treatment for partial epilepsy, is now…

EisaiEuropeFycompaLucentisNeurologicalNovartisPharmaceuticalPricingRegulation

UK pharma group slams NICE for failing to recognize nature of discovery and development

07-12-2012

The Association of the British Pharmaceutical Industry (ABPI) yesterday expressed major concern on behalf…

EsbrietEuropeInterMunePharmaceuticalPricingRegulation

UK's NICE draft guidance recommends Bristol-Myers Orencia for RA

06-12-2012

UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) has today (December…

Anti-Arthritics/RheumaticsBristol-Myers SquibbEuropeOrenciaPharmaceuticalPricingRegulation

Moldova's pharmaceutical market over-regulated, study finds

05-12-2012

According to a study recently released by the Soros Foundation Moldova, the Moldavian pharmaceutical…

EuropeGenericsPharmaceuticalPricingRegulation

Novo Nordisk's Ryzodeg passes regulatory hurdle in Japan; diabetes burden review

03-12-2012

Global insulin market leader Novo Nordisk (NOV: N) of Denmark revealed this morning that its Ryzodeg…

Asia-PacificDegludecDiabetesGlobalHealthcareNovo NordiskPharmaceuticalPricingRegulationRyzodegTresiba

UK's NICE initially negative on InterMune's Esbriet for idiopathic pulmonary fibrosis

30-11-2012

UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) said yesterday that…

BiotechnologyEsbrietEuropeInterMunePricingRegulationRespiratory and Pulmonary

New Zealand updates on Tracleer and sildenafil listing

21-11-2012

New Zealand's Pharmaceutical Management Agency PHARMAC has announced the approval of an agreement with…

ActelionArrow PharmaceuticalsAsia-PacificPharmaceuticalPricingRegulationRespiratory and PulmonarysildenafilTracleer

Australia to add Pfizer's Lyrica to PBS list; call for antibiotic research incentives

18-11-2012

Australia's Health Minister Tanya Plibersek on Friday announced the government's decision to subsidize…

Asia-PacificLyricaPfizerPharmaceuticalPricingRegulationResearch

Gilead HIV drugs Atripla and Truvada to be listed in New Zealand

13-11-2012

Following a consultation, New Zealand's Pharmaceutical Management Agency PHARMAC has announced the approval…

Anti-viralsAsia-PacificAtriplaBiotechnologyGilead SciencesPharmaceuticalPricingRegulationTruvada

Alcon's Nevanac accepted for NHS use in Scotland

12-11-2012

Ophthalmic specialist Alcon, a part of Swiss drug major Novartis (NOVN: VX), said yesterday that its…

AlconEuropeNevanacNovartisOphthalmicsPharmaceuticalPricingRegulation

UK's NICE revokes NHS use of Novartis' Xolair for asthma in children and adults

09-11-2012

The UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE), in draft guidance…

EuropeNovartisPharmaceuticalPricingRegulationRespiratory and PulmonaryXolair

"India Pharma Inc" gearing up for the next level of growth

05-11-2012

Indian pharmaceutical companies will have to rethink business strategy in the light of several interventions…

Asia-PacificGenericsHealthcareMarkets & MarketingPharmaceuticalPricingProductionRegulation

New Zealand decision on proposal for various Novartis products

05-11-2012

Following a public consultation, New Zealand's Pharmaceutical Management Agency PHARMAC yesterday announced…

Asia-PacificNovartisPharmaceuticalPricingRegulation

UK's NICE plans to back NHS use of two breakthrough skin cancer treatments

01-11-2012

The UK's drugs watchdog the National Institute for Health and Clinical Excellence (NICE) this morning…

Bristol-Myers SquibbEuropeOncologyPharmaceuticalPricingRegulationRocheYervoyZelboraf

EMIG calls for greater clarity on value-based medicines from UK Parliamentary inquiry into NICE

31-10-2012

The UK Ethical Medicines Industry Group (EMIG) has welcomed the House of Commons Health Select Committee's…

BiotechnologyEuropePharmaceuticalPoliticsPricingRegulation

Access to many more medicines in Australia, as PBS list extended

28-10-2012

More than 110,000 Australians will benefit from better access to affordable medicines following the Australian…

Asia-PacificBayerEyleaMyforticNovartisPharmaceuticalPricingRegulation

Amgen's Xgeva gets NICE backing for bone metastasis

24-10-2012

New guidance published today (October 24) by the UK's drugs watchdog the National Institute for Health…

AmgenBiotechnologyEuropeOncologyPricingRegulationXgeva

New Zealand's PHARMAC decisions on Roche products

11-10-2012

PHARMAC, the pharmaceutical management agency in New Zealand, has made decisions on the proposal for…

Asia-PacificAvastinHypnovelMabTheraPharmaceuticalPricingRegulationRocheValcyte

UK's NICE draft guidance backs NHS use of Lucentis in DME

05-10-2012

UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE), in new draft guidance…

BiotechnologyEuropeLucentisNovartisOphthalmicsPharmaceuticalPricingRegulation

176 to 200 of 324 results

Company Spotlight

ImmunoGen

ImmunoGen

Back to top